Biotin-Linked Monoclonal Antibody to Toll Like Receptor 4 (TLR4)
| Code | Size | Price |
|---|
| LAA753Hu72-100ul | 100ul | £169.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Minimum order quantity: 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| LAA753Hu72-200ul | 200ul | £229.00 |
Quantity:
| LAA753Hu72-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD284; TOLL; HToll
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Toll Like Receptor 4
Source:
Antibody labeling
Usage:
Western blotting: 1:50-400 <br/>Immunocytochemistry in formalin fixed cells: 1:50-500 <br/>Immunohistochemistry in formalin fixed frozen section: 1:50-500 <br/>Immunohistochemistry in paraffin section: 1:10-100 <br/>Enzyme-linked Immunosorbent Assay: 1:100-1:5000 <br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Monoclonal Antibody to Toll Like Receptor 4 (TLR4) | MAA753Hu22 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||